Y.D. More Investments Ltd Has $2.06 Million Position in OPKO Health, Inc. (NASDAQ:OPK)

Y.D. More Investments Ltd lowered its position in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 18.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 1,395,768 shares of the biotechnology company's stock after selling 318,077 shares during the quarter. Y.D. More Investments Ltd owned about 0.20% of OPKO Health worth $2,059,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Rubric Capital Management LP raised its holdings in shares of OPKO Health by 9.6% during the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company's stock worth $72,573,000 after purchasing an additional 4,284,336 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in OPKO Health by 142.5% during the third quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company's stock worth $2,227,000 after acquiring an additional 876,272 shares during the period. PFG Investments LLC grew its stake in shares of OPKO Health by 9.4% during the 4th quarter. PFG Investments LLC now owns 1,160,885 shares of the biotechnology company's stock worth $1,707,000 after purchasing an additional 99,795 shares during the period. Clearline Capital LP acquired a new position in shares of OPKO Health in the 3rd quarter valued at $1,083,000. Finally, Barclays PLC boosted its stake in shares of OPKO Health by 154.5% during the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company's stock worth $810,000 after acquiring an additional 329,870 shares in the last quarter. Hedge funds and other institutional investors own 64.63% of the company's stock.

Insider Buying and Selling at OPKO Health

In other news, CEO Phillip Md Et Al Frost purchased 47,537 shares of the firm's stock in a transaction on Tuesday, January 28th. The shares were bought at an average cost of $1.47 per share, with a total value of $69,879.39. Following the purchase, the chief executive officer now directly owns 213,234,014 shares of the company's stock, valued at approximately $313,454,000.58. This trade represents a 0.02 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have bought 1,721,609 shares of company stock valued at $2,634,710. Insiders own 47.26% of the company's stock.

OPKO Health Stock Performance

OPKO Health stock traded down $0.01 during mid-day trading on Friday, reaching $1.61. 1,728,203 shares of the company were exchanged, compared to its average volume of 2,882,418. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The firm's 50-day simple moving average is $1.52 and its two-hundred day simple moving average is $1.52. OPKO Health, Inc. has a twelve month low of $0.86 and a twelve month high of $1.76. The firm has a market cap of $1.10 billion, a PE ratio of -8.47 and a beta of 1.63.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.13. The firm had revenue of $173.60 million during the quarter, compared to analysts' expectations of $181.32 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. During the same quarter in the prior year, the business posted ($0.11) earnings per share. Equities analysts predict that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on OPK. StockNews.com cut OPKO Health from a "hold" rating to a "sell" rating in a research report on Wednesday, January 15th. Barrington Research reaffirmed an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a research note on Friday, November 8th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $3.00 target price on shares of OPKO Health in a research report on Wednesday, January 8th.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.